Feed ILMN
IL

Illumina

ILMN · NASDAQ

$222.29 +6.38% (+$13.34)
1M +7.80%
Market Cap $33.6B
P/E Ratio 40.77x
Div. Yield -
ROE 31.08%

Bulios Fair Price

$130.94

41.1% downside

Trenutna cena

$222.29

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ILMN trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
6/9
Valuation
11 /100
Expensive
P/FCF 35.82x
P/S 7.49x
P/B 11.85x
Growth
41 /100
Stable
FCF growth 106.32%
Book val. growth 25.55%
Rev. growth 1.82%
Profitability
96 /100
Strong
Net margin 18.36%
Op. margin 20.97%
FCF margin 20.90%
Quality
83 /100
Excellent
ROE 31.08%
ROA 12.41%
Asset turnover 0.68x
Debt
80 /100
Low
Current ratio 1.80x
Int. coverage 14.53x
Net debt/EBITDA 1.09x
Stability
42 /100
Moderate
Rev. volatility 1.08%
EPS volatility 87.91%
Profitable years 1

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ILMN
Online

O podjetju

Illumina Inc. (ILMN) is an American biotechnology company specializing in the development and production of DNA sequencing and genetic analysis systems. With innovative products and technologies such as the NovaSeq sequencer, Illumina enables researchers and clinicians to conduct advanced genetic studies and diagnostics. The company is known for its emphasis on innovation and research, allowing it to continuously improve its products and expand the possibilities of genetic research. Illumina also collaborates with academic and industrial partners to develop new applications for genetic analysis. Illumina Inc. (ILMN) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on genetics and innovations in DNA sequencing.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Jacob Thaysen

Employees

8,600

Headquarters

San Diego

Prihajajoči dogodki

29 OKT.

Earnings

Upcoming earnings report

43d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.